Kiniksa Pharmaceuticals Ltd expected to post a loss of 14 cents a share - Earnings Preview

Kiniksa Pharmaceuticals International

26/02/2024 14:33

* Kiniksa Pharmaceuticals Ltd  KNSA.OQ   KNSA.O  is expected
to show a rise in quarterly revenue when it reports  results on
February 28 for the period ending December 31 2023
    * The Hamilton Bermuda-based   company is expected to report
a
16.4% increase in revenue to $72.018 million from $61.88 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Kiniksa Pharmaceuticals
Ltd is
for a loss of 14 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kiniksa
Pharmaceuticals Ltd is $28.00​, above​ its last closing price
of $20.00. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.17       -0.17      -0.20     Missed  -19.4
 Jun. 30 2023  -0.17       -0.17      0.21      Beat    225.4
 Mar. 31 2023  -0.22       -0.21      -0.18     Beat    13.3​
 Dec. 31 2022  -0.23       -0.23      0.06      Beat    125.8
 ​​Sep.        0.79        0.78       3.18      Beat    306.4
 30 2022                                                
 Jun. 30 2022  -0.45       -0.44      -0.29     Beat    34.5​
 Mar. 31 2022  -0.40       -0.41      -0.36     Beat    11.5
 Dec. 31 2021  -0.42       -0.42      -0.53     Missed  -26.2
 This summary was machine generated February 26 at 14:33 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)